In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genocea Biosciences closes $35mm Series B

Executive Summary

Vaccines developer Genocea Biosciences Inc. has raised $35mm in its Series B financing round. First-time backers Johnson & Johnson Development Corp., Skyline Ventures (adds a board member), and MP Healthcare Venture Management were joined by returning shareholders Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners, and Morningside Ventures. Funds will support ongoing pipeline development, including the initiation of clinical trials for Genocea's lead vaccine candidate for herpes simplex virus Type 2. The company's early-2009 Series A brought in $23mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register